No scientific studies have established a causal relationship between the Pfizer vaccine and conditions that cause the excessive growth of breasts.

UK women report significant breast enlargement after Pfizer COVID-19 vaccine. Possible link to rare condition PASH, but requires further research.

CEO Albert Bourla expressed modest optimism for Pfizer’s 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

Pfizer's Phase III trial of sasanlimab with BCG in subjects with BCG-naïve, high-risk NMIBC, has met its primary endpoint.